Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
With
American Society of Clinical Oncology
National Institutes of Health (NIH)
This study will look for novel biomarkers of kidney injury in patients receiving cisplatin in patients currently receiving cisplatin.
DNA will be collected both prospectively and retrospectively (from patients that have previously received cisplatin.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prospective Analysis Group
Patients about to receive intravenous cisplatin for the first time as part of cancer chemotherapy.
Aged 18 years and older.
Ability to understand and willingness to sign a written consent document.
Patients may be receiving cisplatin in combination with other chemotherapeutic agents.
Patients may be receiving cisplatin in the context of another clinical trial.
Patients that have previously received intravenous cisplatin as part of cancer chemotherapy.
Aged 18 years and older.
Ability to understand and willingness to sign a written consent document.
Patients that received cisplatin in combination with other chemotherapeutic agents are eligible.
Patients that received cisplatin in the context of a clinical trial are eligible.
You may not be if
Prior receipt of cisplatin.
Patients on dialysis or other renal replacement therapy prior to starting cisplatin.
Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible).
Retrospective Analysis Group
Unable or unwilling to submit to a one-time blood draw.
Clareo Health | Investigation of Cisplatin-Related Kidney Toxicity
